Evidence map›Paper›PMID 37318751›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2023

Methionine-producing tumor micro(be) environment fuels growth of solid tumors.

Alexis A Vega, Erin A Marshall, Avery J C Noonan, Fernando Sergio Leitao Filho, Julia Yang, Greg L Stewart, Fraser D Johnson, Emily A Vucic, Michelle E Pewarchuk, Parag P Shah and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Cancers · 2025
    Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Alexis A Vega *Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, USA.
Erin A Marshall *Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Avery J C NoonanGenome Science and Technology Program, University of British Columbia, Vancouver, BC, Canada.
Fernando Sergio Leitao FilhoCentre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.
Julia YangCentre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.
Greg L StewartIntegrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Fraser D JohnsonIntegrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Emily A VucicNYU Langone Medical Center, New York, NY, USA.
Michelle E PewarchukIntegrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Parag P ShahBrown Cancer Center, University of Louisville School of Medicine, 505 S. Hancock St. Rm 204, Louisville, KY, 40202, USA.
Brian F ClemDepartment of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, USA.
Corey NislowFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Stephen LamIntegrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
William W LockwoodIntegrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Steven J HallamGenome Science and Technology Program, University of British Columbia, Vancouver, BC, Canada.
Janice M LeungCentre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.
Levi J BeverlyBrown Cancer Center, University of Louisville School of Medicine, 505 S. Hancock St. Rm 204, Louisville, KY, 40202, USA. Levi.Beverly@Louisville.edu.
Wan L LamIntegrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
University of British Columbia · CAUniversity of Louisville · USSt. Paul's Hospital · CAGenome British Columbia · CAHigh Throughput Biology (United States) · USNYU Langone Health · US

Funding

Ubiquilins regulate EMT, migration and invasion of human lung cancerR01CA193220 · NCI · UNIVERSITY OF LOUISVILLE · PI BEVERLY, LEVI J · 2015 to 2019
$2.3M
CIHR 143345CIHR Frederick Banting and Charles Best Canada Graduate ScholarshipsNCI NIH HHS R01 CA193220NIH HHS R01CA193220
6 · The paper itself

Abstract

backgroundRecent studies have uncovered the near-ubiquitous presence of microbes in solid tumors of diverse origins. Previous literature has shown the impact of specific bacterial species on the progression of cancer. We propose that local microbial dysbiosis enables certain cancer phenotypes through provisioning of essential metabolites directly to tumor cells.

methods16S rDNA sequencing of 75 patient lung samples revealed the lung tumor microbiome specifically enriched for bacteria capable of producing methionine. Wild-type (WT) and methionine auxotrophic (metA mutant) E. coli cells were used to condition cell culture media and the proliferation of lung adenocarcinoma (LUAD) cells were measured using SYTO60 staining. Further, colony forming assay, Annexin V Staining, BrdU, AlamarBlue, western blot, qPCR, LINE microarray and subcutaneous injection with methionine modulated feed were used to analyze cellular proliferation, cell-cycle, cell death, methylation potential, and xenograft formation under methionine restriction. Moreover, C RESULTS/DISCUSSION: Our results show bacteria found locally within the tumor microenvironment are enriched for methionine synthetic pathways, while having reduced S-adenosylmethionine metabolizing pathways. As methionine is one of nine essential amino acids that mammals are unable to synthesize de novo, we investigated a potentially novel function for the microbiome, supplying essential nutrients, such as methionine, to cancer cells. We demonstrate that LUAD cells can utilize methionine generated by bacteria to rescue phenotypes that would otherwise be inhibited due to nutrient restriction. In addition to this, with WT and metA mutant E. coli, we saw a selective advantage for bacteria with an intact methionine synthetic pathway to survive under the conditions induced by LUAD cells. These results would suggest that there is a potential bi-directional cross-talk between the local microbiome and adjacent tumor cells. In this study, we focused on methionine as one of the critical molecules, but we also hypothesize that additional bacterial metabolites may also be utilized by LUAD. Indeed, our radiolabeling data suggest that other biomolecules are shared between cancer cells and bacteria. Thus, modulating the local microbiome may have an indirect effect on tumor development, progression, and metastasis.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsCell Line, TumorCell ProliferationEscherichia coliGene Expression Regulation, NeoplasticHumansMammalsMethionineRacemethionineS-AdenosylmethionineTumor MicroenvironmentMethionineRacemethionineS-AdenosylmethionineBacteriaLung adenocarcinomaMethionine restrictionMicrobiome

Identifiers

PMID37318751
PMCPMC10697899
OpenAlexW4380680808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.